In a medical note, NAD almost always means “no acute distress” — a clinician’s shorthand for how you looked when they walked in. It is a reassuring observation, not a diagnosis, and it is not a test result.
The second common expansion is “no abnormality detected”, which turns up on reports and results rather than in an examination paragraph. A third is “no apparent distress”, which means the same as the first. And a distant fourth — the one that brings most people to this site — is nicotinamide adenine dinucleotide, the coenzyme sold as an anti-aging therapy. That meaning is essentially never what a chart note is using.
How to tell which one you are looking at
Read the sentence around it. Three quick rules cover almost every case:
- In a physical exam paragraph — next to “alert”, “oriented”, “well-appearing” or a set of vital signs — it is “no acute distress”. The clinician is describing your general appearance.
- Attached to a test, a scan or a sample — an ophthalmology note, a radiology line, a pathology report — it is usually “no abnormality detected”.
- With a plus sign, a milligram figure or a price — NAD⁺, 250 mg, $199 a month — it is the coenzyme, and you are reading marketing rather than a medical record.
If you cannot tell, ask the practice. That is a reasonable question and it costs nothing, and it is a better use of ten minutes than a search result — including this one.
Why an abbreviation this ambiguous survives at all
Because abbreviations save keystrokes for the writer and shift the cost onto every later reader, which is a trade the writer never sees the other side of. A cross-sectional survey handed a list of 20 abbreviations drawn from patient medical records to 46 hospital staff — 15 nurses, 15 doctors in training and 16 consultant physicians (n = 46) — and asked them to write each one out in full. Only 4 of the 20 (20%) were given the intended definition by more than half of the volunteers, the mean score was 6.39 out of 20 (32%), and 75% of the abbreviations had at least one alternative definition [1].
That study did not single out NAD, and we are not claiming it did. What it establishes is the general point: if you are uncertain what three letters in your own record mean, the clinicians reading it may be too, and asking is the correct response rather than an embarrassing one.
If it was the molecule you were looking for
Then the short version is this. NAD⁺ is a coenzyme every cell uses to move electrons through energy metabolism and to fuel enzymes involved in DNA repair. Its availability declines with age, which is the observation the entire supplement and infusion industry is built on.
What is well supported is that oral precursors raise it. In a randomized trial of 80 healthy middle-aged adults taking 300, 600 or 900 mg of NMN daily for 60 days, blood NAD concentrations were significantly higher in every treated group at day 30 and day 60 against both placebo and baseline (all p ≤ 0.001) [2].
What is not supported is the next step — that raising it delivers more energy, sharper thinking or slower aging in healthy people. A systematic review published in early 2026 searched human and rodent intervention studies from January 2010 to October 2025, identified 113 eligible studies including 33 human intervention studies, and found effects on healthspan-relevant outcomes to be heterogeneous and often null, with no eligible outcomes trial at all for intravenous or intramuscular NAD⁺ [3].
From here, our NAD⁺ explainer is the proper starting point, and what the benefits evidence actually shows is the page to read before buying anything. If you are comparing products, the oral precursor board and the injection board are where the prices and formats sit.
One thing worth saying plainly
Seeing NAD in your notes is not a sign that anyone tested your NAD⁺ levels. Routine care does not measure them, there is no standard reference range a clinic could hold you against, and a provider offering to “check your NAD⁺” before selling you a course of treatment is doing something the medical literature does not support. If that is the pitch you are weighing, the regulatory status of these products is the context you want first.